Quality Systems – Page 229

Design Space Missing during PAI readiness: how to document for FDA/EMA/MHRA review

Documenting Missing Design Space for PAI Readiness: A Structured Investigation Approach In the realm of pharmaceutical manufacturing, ensuring that the Design Space is accurately documented ahead of Pre-Approval Inspections (PAI)…

Method Transfer Failure during PAI readiness: decision tree for lab vs manufacturing root cause

Addressing Method Transfer Failures during PAI Readiness: An Investigation Guide In the pharmaceutical industry, method transfer is a critical process, especially during Pre-Approval Inspections (PAI). A failure in this process…

Design Space Missing during PAI readiness: control strategy build-out for inspections

Addressing Missing Design Space During PAI Readiness: Building Out Control Strategies for Inspections In the pharaceutical manufacturing sector, preparing for a Pre-Approval Inspection (PAI) can be complicated, especially when a…

API endotoxin risk in sterile API after drying cycle optimization: control strategy updates for CPPs/CMAs and continued process verification

Optimizing the Drying Cycle for Sterile API: Investigating Endotoxin Risks and Control Strategy Updates In pharmaceutical manufacturing, the optimization of the drying cycle for active pharmaceutical ingredients (APIs) can introduce…

Fill Volume Variability during line setup: investigation steps with CAPA evidence

Investigating Fill Volume Variability in Pharmaceutical Line Setup: A Comprehensive Approach Fill volume variability during line setup can lead to significant compliance challenges in pharmaceuticals, potentially resulting in Out of…

Design Space Missing for long-acting injectables: risk assessment and validation impact analysis

Risk Assessment and Validation Impact Analysis of Missing Design Space for Long-Acting Injectables In the highly regulated landscape of pharmaceutical manufacturing, the absence of a defined design space can lead…

Method Transfer Failure during PAI readiness: control strategy build-out for inspections

Addressing Method Transfer Failures during PAI Readiness: Essential Strategies for Control Build-Out In the pharmaceutical manufacturing landscape, method transfer failures during Process Analytical Technology (PAT) process readiness can lead to…

API genotoxic impurity (GTI) breach after equipment maintenance intervention: how to justify reprocessing vs rejection to FDA/EMA inspectors

Addressing API Genotoxic Impurity Breach After Equipment Maintenance: An Investigation Approach In pharmaceutical manufacturing, identification of a genotoxic impurity (GTI) breach in Active Pharmaceutical Ingredients (APIs) following an equipment maintenance…

Microbial Limits Failure at accelerated stability: GMP documentation for FDA/EMA/MHRA review

Addressing Microbial Limits Failures during Accelerated Stability Testing In pharmaceutical manufacturing, microbial limits failures during accelerated stability testing represent a critical compliance issue with significant implications for product quality and…

Post-Approval Change Failure for innovative delivery systems: risk assessment and validation impact analysis

Analyzing the Impacts of Post-Approval Change Failures in Innovative Delivery Systems In the pharmaceutical manufacturing landscape, ensuring the efficacy and safety of innovative drug delivery systems post-approval is paramount. However,…

Control Strategy Weakness for modified release platforms: risk assessment and validation impact analysis

Addressing Control Strategy Weaknesses for Modified Release Platforms: A Comprehensive Investigation In the world of pharmaceutical manufacturing, particularly for modified release platforms, control strategy weaknesses can lead to significant quality…

Data Integrity Risk during lifecycle management: how to document for FDA/EMA/MHRA review

Managing Data Integrity Risks Throughout the Lifecycle: Documentation for Regulatory Review Data integrity remains a critical concern for pharmaceutical manufacturers, particularly during lifecycle management. The challenge often manifests as deviations,…